Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Status:
Not yet recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The stunning response rate of anti-CD19(cluster of differentiation antigen 19)
auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or
refractory B-cell hematologic malignancies. However, based on open clinical trials, using
patients' T cells might encounter the failure of apheresis available T cells, even if
successful, the time needed for the manufacture could also cause the irreversible disease
progress. Furthermore, the cost of auto-CAR-T cells is not affordable for most patients. So
to provide an accessible and affordable anti-CD19 CAR-T cell therapy for patients with B-cell
hematologic malignancies, we launch such a trial that using the edited T cells from healthy
donors to manufacture universal CAR-T cells and adapt it in patients with CD19+ B-cell
leukemia or lymphoma.
Phase:
Early Phase 1
Details
Lead Sponsor:
Xinqiao Hospital of Chongqing
Collaborators:
920th Hospital of Joint Logistics Support Force 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China Central South University Fujian Medical University Union Hospital Gracell Biotechnologies (Shanghai) Co., Ltd Gracell Biotechnology Shanghai Co., Ltd. Nanfang Hospital of Southern Medical University Second Affiliated Hospital of Xi'an Jiaotong University Tang-Du Hospital The Affiliated Hospital Of Guizhou Medical University The First Affiliated Hospital of Anhui Medical University The First Affiliated Hospital of Kunming Medical College The General Hospital of Western Theater Command The Second Affiliated Hospital of Chongqing Medical University